In a communication to all State and UT Drugs Controllers, CDSCO referred to its earlier letter dated April 11, 2025, which listed certain FDCs as unapproved.
However, following a review, the regulator confirmed that the Voglibose-Metformin sustained release (SR) combination (listed at S. No. 31 in that letter) had already received CDSCO approval. The matter was also taken note of by the Hon’ble Delhi High Court during a hearing on July 14, 2025.
Consequently, the regulator has now formally excluded this FDC from the unapproved list circulated earlier.
A Voglibose-Metformin SR combination is a medication for type 2 diabetes that helps control high blood sugar levels by combining two drugs with different mechanisms of action: Voglibose, an alpha-glucosidase inhibitor, and Metformin, a biguanide.
Voglibose is an alpha-glucosidase inhibitor indicated in the management of postprandial blood glucose in patients with type II diabetes. Metformin is a biguanide antihyperglycemic used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus.
Earlier, the Medical Dialogues Team had reported that the Central Drugs Standard Control Organisation (CDSCO) had issued a stern directive to all State and Union Territory Drug Controllers, instructing them to immediately stop the manufacture and sale of 35 unapproved Fixed Dose Combinations (FDCs), including Metformin Hydrochloride IP (as Prolonged-Release) 500mg and Voglibose IP 0.2mg Tablet.
In its latest communication, the drug regulator noted,
"In this regard, it may be mentioned that one of the FDCs, namely Voglibose 0.2 mg and Metformin HCL (as SR form) 500 mg (at S.No. 31), has been found to be approved by CDSCO and the same was also recorded by the Hon'ble High Court, Delhi, during the hearing on 14.07.2025.
Accordingly, the FDC, i.e., Voglibose 0.2 mg and Metformin Hcl (as SR form) 500 mg (at S.No. 31), stands excluded from the list of unapproved FDCs in the letter dated 11.04.2025."
To view the official notice, click the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.